In this case, we report a novel <i>LDLR-ROS1</i> fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC. The gene discussed is LDLR; the disease is lung adenocarcinoma.